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One of the major symptoms of the neurodegenerative condition Parkinson’s disease
(PD) is a slowness or loss of voluntary movement, yet frustratingly therapeutic strategies
designed to restore movement can result in the development of excessive abnormal
movements known as dyskinesia. These dyskinesias commonly develop as a result of
pharmacotherapy in the form of L-DOPA administration, but have also been identified
following deep brain stimulation (DBS) and intrastriatal cell transplantation. In the case of
L-DOPA these movements can be treatment limiting, and whilst they are not long lasting
or troubling following DBS, recognition of their development had a near devastating
effect on the field of cell transplantation for PD.Understanding the relationship between
these therapeutic approaches and the development of dyskinesia may improve our
ability to restore function without disabling side effects. Interestingly, despite the fact that
dopaminergic cell transplantation repairs many of the changes induced by the disease
process and through L-DOPA treatment, there appears to be a relationship between
the two. In rodent models of the disease, the severity of dyskinesia induced by L-DOPA
prior to the transplantation procedure correlated with post-transplantation, graft-induced
dyskinesia. A review of clinical data also suggested that the worse preoperational
dyskinesia causes worsened graft-induced dyskinesia (GID). Understanding how these
aberrant behaviors come about has been of keen interest to open up these therapeutic
options more widely and one major underlying theory is the effects of these approaches
on the plasticity of synapses within the basal ganglia. This review uniquely brings together
developments in understanding the role of striatal synaptic plasticity in both L-DOPA and
GID to guide and stimulate further investigations on the important striatal plasticity.
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INTRODUCTION
Parkinson’s disease (PD) is a degenerative disease typically associated with aging. Although
previously considered a pure motor disorder, it is now widely recognized that the disease
presents not only with the classically described motor impairments such as tremor, akinesia,
postural instability and rigidity, but in addition most patients also suffer from a range of
non-motor symptoms that can include depression, constipation, dysasthesia and in the later
stages for many patients, dementia (Juri et al., 2008). The pathophysiology of the disease is typified
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by the loss of pigmented nigrostriatal dopaminergic neurons
and also by the presence of ubiquitin and a-synuclein positive
protein inclusions termed Lewy bodies (Spillantini et al., 1997).
However, as with the increased awareness of the diversity
of symptoms, pathophysiology is also more widespread than
the oversimplified perception of PD as being a dopaminergic
disorder; Lewy bodies are spread throughout the peripheral
and central nervous systems and degeneration can be seen
in noradrenergic, serotonergic and cholinergic nuclei although
generally not to the extent of that in the substantia nigra.
Evidence suggests that the Lewy body pathology spreads up
through the brain stem and into the basal ganglia and then
affects cortical areas (Braak et al., 2003). This theory has been
acceptedmore widely with the recognition that this could explain
the pattern of non-motor symptomatology, some which appears
prior to the development of the motor condition. We do note
here though that there is some controversy over the exact
implication of the presence of Lewy bodies in the disease, as some
unusual forms of PD (such as Parkin mutations causing early
onset PD; Takahashi et al., 1994) present without Lewy body
pathology and in contrast incidental Lewy body disease is defined
as the presence of Lewy bodies without clinical signs of PD.
The most widely used treatments for PD focus on enhancing
the activity of the remaining dopamine by preventing its
breakdown [catechol-o-methyl transferase (COMT) or
monoamine oxidase B (MAO) inhibitors] or supplying
exogenous dopaminergic stimulation (in the form of the
dopamine precursor L-DOPA or the dopamine D2-like receptor
agonists). These therapies are highly effective in early stage
disease but as the disease develops their efficacy is limited
and side effects, some of which can be treatment limiting.
Dopamine agonists are associated with a significant risk of
impulse control disorders which are expressed differently
in individual patients but have led to compulsive gambling,
shopping and sexual activity (Weintraub et al., 2010). Increasing
the dose of L-DOPA in combination with other anti-parkinson’s
drugs is the most likely course of treatment as the disease
progresses, but this is associated with a concomitant increase
in the risk of abnormal involuntary movements known as
L-DOPA-induced dyskinesia (LID). As a result of these
limitations on current drug therapy, there is not only a
drive towards a cure for PD, but also improved therapeutic
strategies in the meantime. One such possibility is the
transplantation of dopaminergic neurons into the striatum
in an attempt to replace the missing source of dopamine.
Initially the focus has been on the use of primary fetal
tissues, which has been trialed clinically across Europe and
the US, to prove the principle that the approach has long
lasting clinical efficacy. Latterly, recognizing the limitations
of primary tissues, this has developed into a desire to use
alternative sources of dopaminergic neurons (i.e., stem cell
based sources of cells), but this has yet to reach clinical
trials.
To date, in excess of 100 patients have received a fetal cell
transplant, of those, many have been considered successful,
(interpreted as allowing a reduction in/cessation of their
anti-parkinson’s medication) and remaining better off for
several years following the procedure (for review, see Barker
et al., 2013). However, reports also emerged between 2001 and
2003 of the now-called ‘‘GID’’, dyskinesia that were evident
following transplantation in the absence of L-DOPA (Freed
et al., 2001; Hagell et al., 2002; Ma et al., 2002; Olanow
et al., 2003). The negative effect of this development on the
cell transplantation field as a whole cannot be underestimated.
However, this motor side effect exemplified by L-DOPA, and
subsequently reinforced by cell transplantation, has further
highlighted the need to understand the mechanisms underlying
both induced disorders. Our understanding of dyskinesia in
PD in both of these forms has developed considerably over
the last 10 years and while the phenomenon of GID is
relatively new, the intense scrutiny it has received has also
shed light on mechanisms involved in its L-DOAP induced
counterpart. One common feature of the two disorders may be
the plasticity of striatal neurobiology in the dopamine-deprived
environment of the putamen and the consequences of long
term dopamine replacement. This review focuses on the role
that striatal synaptic plasticity may play in the development
of dyskinesia following both L-DOPA administration and cell
transplantation (see Figure 1 for a summary of influential
factors).
CLINICAL MANIFESTATION OF
DYSKINESIA IN PATIENTS WITH
PARKINSON’S DISEASE
‘‘Off medication’’ dyskinesia (defined as 12 h after the last drug
administration), is a relative rarity in PD patients. In general,
it presents mostly as early morning dystonia in around 16% of
patients with a very small (1%) exhibiting choreic dyskinesia,
which is unrelated directly to their medication regime (Cubo
et al., 2001), but can be a complication of long term drug therapy.
The more commonly associated dyskinesia in PD patients is
the LID present during the period of L-DOPA activity during
the day. Two main types of LID are described, the first, and
best characterized being ‘‘peak dose dyskinesia’’; monophasic,
typically choreiform in nature, purposeless and non-rhythmic
and often affecting the more severely parkinsonian side of the
body to a greater extent. They appear as the plasma L-DOPA
levels peak and are sustained until they decrease, typically
covering much of the effective period of the drug (2–3 h). It is
noteworthy though, that there is no direct correlation between
the severity of peak dose dyskinesia and the exact peak plasma
levels of L-DOPA reached, severity in fact being related to other
factors including emotional stress (Mones, 1970; Nutt, 1990). The
movements can be very intrusive and patients are highly averse to
this in the early stages of their disease course making them very
wary of L-DOPA, although this attitude does shift as dyskinesia
become established and patients are faced with the choice of
limited movement vs. mild dyskinesia (Khlebtovsky et al., 2012).
The second form of LID is diphasic dyskinesia, appearing as the
effective dose of L-DOPA onsets and wanes with a dyskinesia free
period of symptomatic relief in between. This suggests, that in
contrast to the peak dose dyskinesia associated with high plasma
L-DOPA, these are associated with a critical but low level of
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FIGURE 1 | Schematic illustration of the factors suggested to be involved in dyskinesia mediated by L-DOPA or dopaminergic cell transplantation.
A DA denervation such as that in PD causes the loss of DA buffering capacity by endogenous nigrostriatal terminals in the striatum. Together with pulsatile drug
delivery from L-DOPA pharmacological administration. This leads to excessive swings of striatal DA, a causative factor for dyskinesia. Transplants may create
inadequate or incomplete reinnervation from a graft or lack of synaptic integration may have a similar effect. The 5-HT system is proposed as having a role as a
compensatory DA release site in the absence of residual DA axonal terminals in the striatum, similarly transplanted 5-HT neurons may also disrupt dopaminergic
regulation. Our understanding of the inflammatory contributions are more limited but it is conceivable that low grade inflammatory responses present as an intrinsic
part of the disease, or as a reaction to an incompatible element of the transplant contributes to aberrant neuronal activity. On the postsynaptic side of the striatal
neurons (orange box) the stand supersensitive dopamine receptor responses as well as aberrant synaptic features on MSN spines and graft connections that
altogether cause an altered synaptic plasticity with abnormal LTP and LTD which may underlie the abnormal behaviors seen in both LID and GID.
circulating L-DOPA or dopamine, likely to be stimulating the
increasingly sensitized dopamine receptors. Phenomenologically
this form of dyskinesia are more typically associated with the
lower limbs, and are more dystonic in nature, often affecting
patients with a younger onset of disease. There is a lot less known
about diphasic LID and hereon in LID will be used to refer to
peak dose LID.
The exact incidence of peak dose LID in PD is hard to
estimate, given the variance in trial design and lack of recognition
of mild dyskinesia by patients themselves (Pietracupa et al.,
2013). Indeed estimates vary from 0% up to 50% of patients in
the first year of treatment (reviewed in Manson et al., 2012),
to 94% at 15 years of treatment (Hely et al., 2005), while
others estimate the risk to be around 10% per year of L-DOPA
exposure (Ahlskog and Muenter, 2001). In those patients that
are affected, the impact of LID on quality of life is clear
from several studies, affecting mobility, communication and
emotional well-being (Encarnacion and Hauser, 2008; Montel
et al., 2009). There is no doubt that it is a hugely variable
condition and it is still accepted that LID, in some form, are
an almost inevitable part of PD for most patients. The only
available treatment is the anti-viral amantadine, which has some
benefit for a period of time but long-term efficacy is limited.
Nevertheless, with a greater understanding of the medications
and tools at the disposal of clinicians, patients with overt, severe
dyskinesia are a relative rarity compared to years gone by.
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The remaining concern is that patients may not be receiving
the full potential anti-parkinsonian benefit of the drugs on
offer, as treatment is limited in order to effectively control the
risk of LID. Importantly, as new therapies are developed the
plastic changes that long term L-DOPA evokes in the brain may
influence the efficacy of these therapies or the side effects they
generate.
As a result of the limitations LID generation imposes on
L-DOPA treatment, and to ameliorate some of the symptoms
that L-DOPA does not address (tremor being the classic
example), alternative therapies are constantly being explored.
One significant surgical intervention, which has become used
world-wide over the last 15 years, is deep brain stimulation
(DBS) in which electrodes delivering high frequency stimulation
are implanted bilaterally into the subthalamic nucleus. This
has the immediate effect of reducing motor symptoms and
alleviating the need for high dose L-DOPA therapy and many
patients are able to reduce their medication significantly once
the stimulators are turned on, and consequently their LID. There
have been case reports of both DBS and subthalamotomy in
which L-DOPA independent dyskinesia were observed following
surgery, although resistant to amantadine these movements
resolved themselves, in one case within minutes of turning
off the stimulator (Brodsky et al., 2006), in others, within
6 months of the surgical intervention (Merello et al., 2006).
These data are useful in that they give clues as to how the
pathophysiologymay vary from that of LID, which is amantadine
responsive to a degree. DBS is not a focus for the review but
worthy of mention as it demonstrates clearly that alternative
basal ganglia circuitry may contribute to the generation of
dyskinesia.
A third and further cause of dyskinesia in PD has been
described over the last 14 years, an intractable form of
dyskinesia that has appeared as a result of intrastriatal fetal
cell transplantation. The first published report in 2001 reported
‘‘runaway dyskinesia’’ 6–12 months post transplantation in
five patients (out of a total transplanted cohort of 33; Freed
et al., 2001). Persistent generalized dyskinesia or movements
specifically located to the arm was described. This was followed
up by two other clinical trials reporting hyperkinetic movements
and repetitive stereotypic movements of the limbs (Hagell et al.,
2002; Olanow et al., 2003), one follow up report likened the
movements to those observed during biphasic dyskinesia, and
similarly inferred that the cause might be suboptimal levels
of dopamine (Olanow et al., 2009), as opposed to the initial
hypotheses of excessive or patchy putaminal dopaminergic
innervation (Ma et al., 2002).
For the majority of patients, the overall severity of these
movements was clinically considered to be relatively mild,
especially in comparison to L-DOPA induced dyskinesia. Many
patients failed to recognize the symptoms themselves, and in
a European cohort the full incidence required independent
review of video footage (Hagell et al., 2002). In the majority
of cases the patients’ responses to amantadine are not well
documented, but only a handful have gone on to require
additional interventions, which have been DBS of either the
STN or GPi. Although the incidence may appear relatively
small, this is out of a reported total of less than 70 patients,
giving an average frequency of 39% across three clinical trials
(more have been transplanted worldwide but with limited
follow up and lack of consistent and complete reporting; Lane
et al., 2010). Taking into account some implicit reports of
aberrant movements post transplantation (reviewed in Lane
et al., 2010) this average across six trials is still 32% of
patients and therefore demonstrates a significant concern in the
development of transplantation as a reliable and safe therapy
for PD.
ANIMAL MODELS OF DYSKINESIA
Before going on to discuss current knowledge of the mechanisms
underlying LID and GID, it is worth highlighting how these
types of dyskinesia are represented in the most commonly
used animal models of PD (reviewed in more detail in Carta
et al., 2006; Smith et al., 2011 and elsewhere). Historically both
the 6-OHDA lesioned rodent and MPTP-treated primate have
been used as models for peak dose LID, whilst the study of
surgically related dyskinesia (DBS and transplantation) has, for
practical reasons, been studied more selectively in the rodent
model. Importantly there are limited studies of the mechanisms
underlying end of dose or diphasic LID, and they are not
well represented in animal models. The longevity of the peak
dose LID model is supported by excellent face validity in
the primate in particular (Carta et al., 2006) but also clear
behavioral and neurochemical parallels can be identified in
the rodent models (Cenci et al., 1998). Although in many
cases neurobiological changes identified in the models are also
observed in patient materials, the resulting development of
effective novel therapeutic approaches has been frustratingly
elusive, with many therapies failing at early clinical stages (Fox
et al., 2006). At least in models of LID there is a clinically
limited but effective pharmacological therapy in the form of
amantadine, against which the animal models can be, and
have been validated (Blanchet et al., 1998; Lundblad et al.,
2002), the same cannot be said for GID for which no such
validation is possible. Developing an animal model of GID is
more complex. In patients the behavior is spontaneous and
presents in the absence of drugs, yet observational studies in
both primates and rodents with dopaminergic lesions and fetal
cell transplants have not revealed any consistent, persistent
abnormal behaviors (Lane et al., 2006; Redmond et al., 2008;
Vinuela et al., 2008). Cost and practical limitations have thwarted
attempts to explore GID in detail in primates, while two models
of GID exist in rodents but both of which depend upon
the exogenous administration of drugs to elicit the abnormal
responses directly contrasting the ‘‘off medication’’ status of
patients. The administration of L-DOPA and amphetamine
post-transplantation produces different behaviors in the rat
following transplantation that have been used as a proxy
measure for true GID (Lane et al., 2006; Maries et al., 2006).
This is discussed in more detail elsewhere (Lane, 2011 and
others) but highlights the complexity of preclinical investigations
into this field. In as far as is practically possible, some
patients with GID have been reviewed and there has been
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a very interactive process to take hypotheses based on this
patient data into preclinical studies and vice versa. There is
however the significant lack of post-mortem study of any
patient with cell transplantation and a recorded development
of GID.
THE STRIATUM, A PLACE OF
HETEROGENOUS PLASTICITY
The caudate putamen, a single anatomical entity in rodents,
is composed of a complex mosaic organization that can be
divided into several functional compartments in rodents based
on (i) different cortical afferents e.g., to the ventromedial vs.
the dorsolateral striatal subregion; (ii) the patch and matrix
compartments; or (iii) the direct or indirect efferents of the
striatal medium-sized spiny neurons (MSNs; Gerfen, 1992;
Crittenden and Graybiel, 2011), all of which must be considered
for their role and vulnerability in the face of long term L-DOPA
administration. There are indications that the striatal plasticity
that underlies dyskinesia induced with L-DOPA or graft share
the same neuropathologies or at least are linked with each
other. Firstly, most transplantation patients experiencing GID
had presented preoperatively with established LID; secondly,
prior exposure to L-DOPA and development of LID is necessary
for, and correlated to, the induction and severity of GID post
transplantation in rodentmodels (Lane et al., 2009; Steece-Collier
et al., 2009; García et al., 2011a). Potentially mechanistically
key to this relationship between LID and GID, are the plastic
changes which occur in subregions of the striatum in response
to repeated, pulsatile exposure to L-DOPA administration and
that correlate with the development of LID.
Dyskinesia can be seen as an aberrant form of plasticity
where DA derived from L-DOPA or possibly transplanted
neurons, causes long-lasting molecular and behavioral changes
in the dopamine denervated environment (see Figure 1). This is
particular evident on glutamatergic synapses where both pre and
postsynaptic mechanisms of the MSN are involved. Accordingly,
dyskinesia is improved by treatments that either stabilize
extracellular DA levels or dampen the supersensitive response
of MSN. The relative contribution of pre- vs. postsynaptic
mechanisms may differ among dyskinetic subjects, making
them more or less responsive to different treatment options.
Presynaptically, a lack of autoregulatory machinery for the
DA release leads to excessive swings of extracellular DA after
L-DOPA administration that has been considered a primary
cause of dyskinesia (Lindgren et al., 2010). In the severely
DA denervated brain L-DOPA can even instead be taken
up, converted and released by 5-HT axonal terminals that
compensate for the denervation of their neighbor DA neurons
(see ‘‘Discussion’’ below; Figure 1). The postsynaptic plasticity
includes upregulation of transcription factors and plasticity genes
in the striatal MSNs with changes to striatal D1 andD2 dopamine
receptor expression (Blanchet et al., 1995; Andersson et al., 1999;
Konradi et al., 2004; Cenci and Lundblad, 2006). This increased
sensitivity is reflected in abnormally high and sustained levels of
both opioid precursor genes and∆FosB-like transcription factors
(Doucet et al., 1996; Andersson et al., 1999; Hagell and Cenci,
2005; Lindgren et al., 2011). Once instigated, these alterations
in receptors levels remain, even in the absence of dopaminergic
stimulation. Behaviorally this is reflected clinically in a rapid
reinstatement of LID upon re-exposure to L-DOPA after a
period of withdrawal in animal model (Andersson et al., 2003).
Similarly in the clinic a drug holidays from L-DOPA fail to
improve the incidence of LID (Rascol, 2000). The upregulation
of receptor signaling is accompanied by a pronounced activation
of downstream elements to the D1 receptor, e.g., ERK1/2 (Pavón
et al., 2006; Santini et al., 2007; Westin et al., 2007). D1 receptor
signaling pathway has recently shown to be modulated by the
D3 receptor, that thereby could modulate the development of
LID (Solís et al., 2015). This D2 subclass family member has low
levels in dorsal striatum but there has been evidence of increase
receptor expression after L-DOPA dyskinesiogenic treatment
(Bezard et al., 2003).
Even if the striatum is generally considered to be a
homogenous structure recent developments have shown an
important heterogeneity that should be taken into account
when studying striatal plasticity and also synaptic plasticity
(see below). Initial analyses of anatomical and biochemical
data pointed to the lateral striatum has having a specific role
in the generation of these abnormal behaviors. Upregulation
of Na+K+-ATPase occurs specifically in the lateral striatum
suggesting increased neuronal activity of MSNs in this location
(Konradi et al., 2004). An increased expression of glutamate
transporter that could underlie an increased glutamate release,
also implicates this region. Similarly a striatal induction of∆FosB
affects primarily the lateral striatum and the direct pathway
MSNs in dyskinetic animals (Doucet et al., 1996; Andersson
et al., 1999), consistent with the upregulation of D1 receptors.
These and other data imply that LID may result from high,
intermittent stimulation of striatal dopamine receptors causing
sustained downstream changes in gene and protein expression
(Cenci et al., 1998; Konradi et al., 2004). While the degree
of nigrostriatal dopaminergic loss is a strong causative factor
in LID, strength for a post-synaptic root cause for LID also
comes from other conditions in which LID have been reported.
L-DOPA is also used in the management of inherited defects
of dopamine synthesis and DOPA-responsive dystonia and LID
have been reported in both conditions (Hwang et al., 2001; Pons
et al., 2013). The LID are phenomenological similar in their
presentation but importantly the dopaminergic terminals are still
intact and presumably able to regulate the conversion of L-DOPA
to dopamine and the release of dopamine into the synaptic cleft.
Although there is much to learn about these conditions it would
implicate the post synaptic receptors and abnormal stimulation
as a potential cause (Bezard, 2013).
More detailed regional analysis has subdivided the lateral
striatum into ventro and dorso-lateral areas and highlighted
specific LID-related plasticities in the ventrolateral areas.
Among these have FosB expression selectively in ventrolateral
areas been linked to forelimb and facial LID (Maries et al.,
2006). Moreover, alterations in the glutamate receptors on
the postsynaptic compartments with increased expression of
N-methyl-D-aspartate (NMDA) and AMPA 2-amino-3-(5-
methyl-3-oxo-1,2-oxazol-4-yl)propanoic acid subunits in the
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ventrolateral compared to the dorsolateral striatum (Rylander,
2013). These differences in subunit expression turned out to
have a particular role in the later discussed corticostriatal
synaptic plasticity (Calabresi et al., 2007; Cenci and Konradi,
2010) shifting the probability and degree of LTP in striatal
compartments (Rylander, 2013). These data demonstrate that
striatum is not as a homogenous region as previously believed
and region specific changes could easily be missed.
It has been hypothesized that the plastic changes initially
induced with LID can also be linked to the generation of
GID. In this hypothesis inhomogenous dopamine re-innervation
of the host-putamen after dopamine fetal transplantation are
believed to cause excessive dopamine release in ‘‘hotspots’’
that in turn would activate the aforementioned supersensitive
signal transductionmechanisms of the dopamine-signal pathway
similar to LID (Ma et al., 2002). This is based on early
findings that prior long-term exposure to L-DOPA may already
have induced this altered profile of dyskinetic behavior prior
to transplantation. In support of this, amphetamine-induced
rotational behaviors following transplantation (as a model for
GID in rodents), are associated with an abnormally high
expression of c-Fos in striatal regions innervated by the graft-
derived DA axons (Cenci et al., 1992; Muñoz et al., 2003; Lane
et al., 2009). However, if this were the only explanation for
GID we might expect to see an irregular downregulation of the
supersensitive dopamine receptors relating areas of high and
low reinnervation, or a correlation between c-Fos expression
and the expression of non rotational abnormal movements.
Certainly in rodents this has not been the case, there is no
correlation between the c-Fos activation and generation of
amphetamine-induced abnormal movements and both fosB and
dopamine receptor levels appear to normalize relatively evenly
in the areas of graft innervation (Lane et al., 2009; Smith et al.,
2012). Even good grafts are currently not able to innervate with
complete homogeneity throughout the striatum so it remains
possible that non-reinnervated areas remain supersensitive and
trigger these behavioral response. Although the relationship
of GID to pre-existing LID is reasonably strong, thus far
the mechanisms are elusive, and it may lie in other areas of
plasticity.
SYNAPTIC PLASTICITY IN LID
The corticostriatal synapse between the glutamatergic cortical
efferent and striatal MSNs has proven to be essential for
movement improvement after L-DOPA or transplantation of
dopaminergic cells. In animal models has it been possible to
examine the functional andmorphological state of these synapses
and using these has shown severe morphological alterations of
the striatal MSNs, including shrinkage and loss of dendritic
small protrusions, the spines in the PD state (Ingham et al.,
1998; Fieblinger et al., 2014) . The intrinsic excitability and
synaptic connectivity has further been altered in the PD state
and in LID (Fieblinger et al., 2014). Structural changes cause
loss or reorganizations of the corticostriatal synapses and thereby
interfere with its signaling through the classical bidirectional
synaptic plasticity, i.e., long-term potentiation (LTP) and
long-term depression (LTD). Both LTP and LTD are widely
expressed at excitatory synapses throughout the brain and have
been described at corticostriatal synapses where they are believed
to underlie motor-skilled learning, cognitive performance and
reward mechanisms (Calabresi et al., 2007). The induction
of synaptic plasticity here requires interaction of DA and
other neurotransmitters including glutamate function through
ionotrophic (NMDA and AMPA) as well as metabotropic
receptors but also acetylcholine, nitric oxide and endogenous
cannabinoids (Calabresi et al., 2007; Shen et al., 2015). Not
surprisingly are both LTP and LTD absent or severely altered
in rats with a dopaminergic denervation (Picconi et al.,
2003; Paillé et al., 2010) but whether this loss of synaptic
plasticity can be fully restored by DA pharmacotherapy or
cell therapy has not been extensively studied: in rats with
6-OHDA lesion a restoration in LTP has been seen in the
dorsolateral striatum with chronic L-DOPA administration, a
situation which is then confounded by the development of
LID (Picconi et al., 2003). Certainly, the initial loss of spine
and dendrites on the MSNs after a DA-denervation may
impede a proper restoration of the synaptic connections by any
dopaminergic therapy, L-DOPA or DA fetal transplants (Zhang
et al., 2013) as this is the main site of dopamine/glutamate
interaction.
As one of the consequences to the morphologically altered
MSNs a non-physiological corticostriatal plasticity has been
repeatedly shown in both rodent models and in patient with LID
(Calabresi et al., 2007;Morgante et al., 2006). In the rat PDmodel,
LID associates to irreversible LTP of the striatal MSN, which fails
to depotentiate (Picconi et al., 2003) and with persistent deficits
in LTD in the same neurons (Picconi et al., 2011). A recent paper
further links an aberrant LTP in specifically the direct pathway
MSN with LID and involve a cholinergic muscarinic receptor
modulation (Shen et al., 2015). Also, in the clinics, has deficit in
LTP-like plasticity been detected but then in the motor cortex.
Only after L-DOPA treatment that did not cause dyskinesia could
the plasticity be normalized (Morgante et al., 2006).
In an attempt to unravel the mechanisms behind LID
associated plasticity, one has looked into alterations in the
glutamate receptors that are involved in LTP and LTD. Here,
an increased expression of a particular AMPA receptor subunit,
i.e., the alternatively spliced calcium-permeable subunit, has
been linked to LID in the rat (Kobylecki et al., 2013). Also,
striatal NMDA/AMPA receptor ratio and abnormal receptor
distribution between synaptic and extrasynaptic sites might
disturb the function of the glutamatergic synapse and account
for the pathological plasticity seen in LID (Gardoni et al., 2006;
Mellone et al., 2015). L-DOPA treatment fails to rebalance the
physiological synaptic parameters in NMDA/AMPA receptor
ratio after a PD lesion, in contrast to a non-dyskinesiogenic
treatment (Bagetta et al., 2012). Adding further weight to the
relationship between this impaired signaling and the behavioral
output correcting the NMDA subcellular distribution through
the use of cell permeable peptides has been associated with
attenuation of LID (Gardoni et al., 2012). Recent developments
have pointed to specific structural changes of dendritic spines
in the striatum suggesting a disrupted balance between direct
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and indirect pathway neurons and an aberrant action selection
in the basal ganglia. Here, using combined electrophysiology and
three-dimensional reconstructions of transgene labeled MSNs,
studies have pointed to a remarkable regrowth of spines on
the indirect pathway neurons after L-DOPA treatment that
was initially lost by the DA denervation, a regrowth that
is correlated to dyskinesia in mice (Suárez et al., 2014). In
contrast, the direct pathway neurons show no change in spine
numbers but instead an elevated excitability in PD and supressed
excitability in LID models (Fieblinger et al., 2014; Suárez et al.,
2014). Data by Zhang et al. (2013) further links dyskinesia
to altered synaptic contacts of the corticostriatal glutamatergic
synapses onto the spines of MSNs. An imbalance between
corticostriatal and thalamostriatal pathways is here proposed to
contribute to the persistent LTP seen in dyskinesia. Ultimately
it is clear that the structure and receptor composition on the
corticostriatal synapses are an important component recovery
from dyskinesia.
SYNAPTIC PLASTICITY AFTER CELL
TRANSPLANTATION IN PD
Even though transplanted neurons are able to innervate the host
striatum, release DA, and reverse alterations in neuropeptide
expression after a dopamine denervating lesion (Cenci et al.,
1993) it is unclear whether they restore the synaptic network
in the PD brain or if they cause further alterations in synaptic
plasticity. The importance of this question lies in the fact that
a functional integration from the grafted neurons into the host
microcircuits with formation of bidirectional synaptic contacts
between the host and grafted neurons would give superior
therapeutic benefit than a mere neurochemical restoration
(Rylander et al., 2013). Furthermore it will be of great relevance
for novel cell therapies that are currently developing e.g.,
human embryonic stem cell derived neurons that have been
shown to generate DA neurons with an authentic midbrain
phenotype that survive transplantation and can restore motor
deficits and synaptically be integrated from host neurons (Kriks
et al., 2011; Grealish et al., 2014). It has been suggested
that neural grafts go beyond that of simple DA delivery and
involves more complex mechanisms of functional integration
that lead to more substantial motor recovery. A clinical study
has shown a delayed recovery in motor cortical activity occurring
first after 18 month post-transplantation compared with the
more direct increase in DA storage capacity that was detected
with [18]F-dopa position emission tomography by 6 months
post-transplantation (Piccini et al., 2000). Also, in animal models
of PD, the capacity for DA synthesis and storage in the grafts
is detected well before a significant improvement in complex
sensory motor behavior (Annett et al., 1995; Winkler et al.,
1999).
Few studies have explored cell-transplant integration in PD
brain using electrophysiology. Nevertheless’ recent advances in
optogenetic and chemogenetic tools as well as transynaptic
labeling (Tønnesen et al., 2011; Grealish et al., 2014; Torper
et al., 2015) combined with electrophysiology allows for
more delicate measurements of transplants integration in the
future. Previous extracellular electrophysiological recordings
have shown that dopaminergic fetal neurons partially restore
spontaneous neuronal firing in the striatum up to 2 mm
from the core of the grafted area (Di Loreto et al., 1996;
Stromberg et al., 2000) and also restore neuronal activity in
the subthalamic nucleus (Rumpel et al., 2013). Yet only one
study has explored the synaptic plasticity in striatal MSNs
after fetal cell transplantation (Rylander et al., 2013). Here
transplants of DA neurons were shown to partially restore
activity-dependent LTP (see Figure 2D) in contrast to 5-HT-
rich transplants. Importantly to the field of PD cell-therapy, the
restoration of LTP was accompanied with a partial restoration
in motor deficits in rats at 7–10 weeks post-transplantation
(Figure 2). The restoration in synaptic plasticity was specifically
seen in the ventrolateral striatum that received sufficient DA fiber
innervation from the transplants and where grafted fibers are
known to form synapses (Doucet et al., 1989). In the dorsolateral
striatum, where the DA re-innervation was less (about 45%),
the grafted DA neurons were not able to restore any type of
synaptic plasticity deficits. Taken together these data suggest that
the function of DA transplants goes beyond that of simple DA
delivery and involves more complex mechanisms of functional
integration that lead to more substantial clinical recovery. This
most probably involve restoration of synaptic plasticity and
possibly forming anatomically appropriate connections capable
of influencing host behavior. Yet is still not known whether or
not restoration in synaptic plasticity occurs as a consequence of
altered synaptic rearrangements or as a precise reconstruction
of the original physiological connections or how that would
be affected by dyskinesia as these rats were not tested for
that.
Based on the results above, the restoration of synaptic
plasticity could be seen as an indicator for successful graft
integration that underlies motor improvement. The fact that the
restoration was limited to the most richly reinnervated regions
might explain the limited efficacy of DA transplants in alleviating
clinical symptoms and supports a multisite-grafting procedure to
more extensively restore the plasticity in the whole parkinsonian
putamen (Rylander et al., 2013). Indeed multisite transplantation
of DA graft is superior to single-site ‘‘hot-spot’’ DA grafts
because it lead to functional recovery and lower incidence of
GID (Maries et al., 2006). This notion is supported by a clinical
PET study (Ma et al., 2002). On the other hand the incidence
of GID is positively correlated with the amount of grafted tissue
(Hagell et al., 2002; Lane et al., 2006). Hence there seem to be
a delicate balance between functional integration of the grafted
neurons with motor restoration on one hand and development
of GID with possible pathological synaptic integration on the
other.
Previous studies have evidenced that striatal DA grafts form
aberrant connections with host MSNs (Freund et al., 1985;
Mahalik et al., 1985) that has further been correlated with GID
(Soderstrom et al., 2008). Transplanted DA neurons synapse
onto MSNs with increased proportion of asymmetrical and
perforated synapses in both parkinsonian rats and monkeys
(Leranth et al., 1998; Soderstrom et al., 2008), synaptic
specializations that are exacerbated in rats with GID-like
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FIGURE 2 | Synaptic plasticity can be restored by fetal transplants. Adapted from Rylander et al. (2013), with permissions. (A–C) Photos from TH
immunohistochemistry show the growth of transplanted DA neuron projections in striatum. The 6-OHDA lesion produced a unilateral DA denervation (B) that DA
graft were able to partly reinnervate (C) along with a gradual improvement in akinesia (not shown). (D–F) Grafted DA neurons can restore LTP close to the graft. In
the reinnervated region electrophysiological recordings of striatal medium-sized spiny neurons (MSN) show a restoration in long-term potentiation (LTP) in DA grafted
animals (triangles) compared to animals with 6-OHDA lesion only. Left panel represents the traces for the evoked excitatory post-synaptic potential (EPSP) pre- and
post HFS (the stimulating protocol for LTP induction).
behaviors (Soderstrom et al., 2008). Asymmetrical synapses in
turn have been associated with excitatory neurotransmission
(Peters and Palay, 1991) and perforated synapses with elevated
excitatory activity and LTP (Marrone and Petit, 2002) raising
the possibility that the synaptic connection would alter
the synaptic plasticity within the grafted region to a form
that is associated with dyskinesia (Picconi et al., 2003;
Morgante et al., 2006). As the morphological aberrations occurs
via a dysregulation of Cav1.3 L-type calcium channel, the
aberration can be prevented by the in vivo administration
of an L-type calcium channel antagonist (Soderstrom et al.,
2010). This reduces not only LID (Schuster et al., 2009)
but also the development of GID in the rat (Soderstrom
et al., 2010). The data suggests that improved synaptic
connection between the transplants and host neurons would
effectively relieve PD symptoms through restoration of synaptic
plasticity.
SEROTONIN AND DYSKINESIA
There are several non-dopaminergic systems that have shown to
play important roles in the development of dyskinesia, among
which a major player is the serotonin (5-HT) system. There
is both a variable loss of 5-HT in the parkinsonian brain
and significant numbers of 5-HT neurons are transplanted
alongside the dopaminergic neurons in the primary graft
preparation, creating a dynamic of host striatal serotonin
deficiency and excessive post transplantation innervation that
has to be reconciled. The 5-HT system has a remarkable
capacity for compensatory sprouting after either a serotonergic
or dopaminergic denervation (Radja et al., 1993; Maeda et al.,
2005) and recently a maladaptive plasticity of this system has
been linked to LID (Rylander et al., 2010). Long-term L-DOPA
pharmacotherapy to the PD brain causes an increased striatal
density of 5-HT axonal fibers that has been positively correlated
with the severity of LID in both rat and primate models as
well as in post-mortem tissue from PD patients (Rylander et al.,
2010). The results have been supported by a recent clinical
study where increased binding of [11C]DASB PET binding
indicating a higher 5-HT fiber density was detected in patients
with LID compared to stable L-DOPA responders (Politis et al.,
2014).
Recent discoeries from rat and primate models of PD
suggest multiple mechanism of action through which the 5-HT
system may contribute to LID. Of these the DA-releasing
role has emerged as one of the concepts. In the DA-
denervated brain the serotonergic terminals are especially good
candidates for converting exogenously administered L-DOPA
into DA (Tanaka et al., 1999; Lindgren et al., 2010). The
release from the 5-HT terminals facilitates the therapeutic
action of L-DOPA by facilitating the conversion of L-DOPA
to DA and thus relieving PD motor symptoms, but the
raphe-striatal serotonergic terminals lack an auto-regulatory
feedbackmechanism for DA release and cause an aberrant release
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with excessively high DA levels in the extracellular space as a
consequence. Such fluctuations, between high and low DA levels
may compound the pulsatility of dopamine in the brain and
exacerbate receptor sensitivity and therefore the responses of
striatal neurons to trigger LID (Carta et al., 2007; Lindgren et al.,
2010).
The developing dorsal raphe is close in proximity to
the ventral mesencephalic area dissected and suspended for
transplantation in PD and are hard to exclude in their
entirety during the dissection without compromising the yield
of dopaminergic neurons. Post mortem and imaging data
illustrates that these 5-HT neuronal populations vary in extent
between transplanted cohorts but can be extensive (Mendez
et al., 2005; Politis et al., 2010). As 5-HT grafted neurons
do not form synaptic contacts to the same extent than DA-
grafted neurons (Mahalik and Clayton, 1991) but still retain
the capability to release excessive amounts of unregulated
DA it has been postulated that they may contribute to the
development of post-transplantation dyskinesia. Importantly,
preclinical data shows no correlation between grafted 5-HT
content and GID (Lane et al., 2006) and a negative effect
is only seen with an unfavorable DA/5-HT ratio (Carlsson
et al., 2007; García et al., 2011b). Accordingly, clinical PET
imaging studies have reported prominent graft-derived 5-HT
innervations and a higher 5-HT/DA ratios in patients with
GID (Politis et al., 2010; Politis and Loane, 2011; although
it must be noted that no patients with successful grafts
without GID have been scanned for comparison). This story
is less than complete, as some data indicates that grafts with
some 5-HT content produce better functional recovery and
pharmacological assays to try and tease out this relationship
have been inconclusive. Low doses of the 5-HT1A autoreceptor
agonist buspirone were able to attenuate the GID observed
in patients (Politis and Loane, 2011) but preclinical studies
suggest that this may occur through a dampening aberrant
activity of the dopamine receptors. The 5-HT reuptake inhibitors
fluvoxamine significantly increases the severity of GID (Lane
et al., 2006) and direct activation of 5-HT1A and1B auto-
receptors significantly reduces GID in rats via the presynaptic
host-derived 5-HT system (Shin et al., 2012). However, while
transplanted rats show an attenuation of amphetamine-induced
abnormal movements upon buspirone administration in the
same way as patients GID is reduced, this effect seems to be
independent of the 5-HT system and rather acting via the DA
D2 receptor (to which buspirone acts as an antagonist; Shin
et al., 2012). These results point to a critical role of both
5-HT1 and D2 receptors in the modulation of GID, and suggest
that 5-HT neurons may exert a modulatory role (Shin et al.,
2012).
INFLAMMATION AND DYSKINESIA
Inflammatory processes are certainly active in the parkinsonian
brain with pathological evidence of upregulated microglia
and positive benefit from long term administration of non-
steroidal anti-inflammatories (reviewed in Wang et al., 2015).
However, there is limited understanding of the role of the
immune system in the generation of LID likely to be due
to the lack of an appropriate animal model. The only
clinically available treatment for LID, amantadine has been
shown to have anti-inflammatory properties (Ossola et al.,
2011) and other approaches have found that molecules with
anti-inflammatory activity may help reduce LID severity
or onset (Barnum et al., 2008; Aron Badin et al., 2013;
Bortolanza et al., 2015). Importantly in the context of striatal
plasticity anti-inflammatories have been shown to improve
spine abnormalities in mouse models of Huntington’s disease,
a link that may be worth further investigation (Simmons et al.,
2013).
Clinical observations have coupled GID to the host immune
system; GID has been reported in patients that received no
immunosuppression (Freed et al., 2001) or soon after withdrawal
of immunosuppression, suggesting that some degree of graft
rejection and local inflammatory response may have caused GID
(Olanow et al., 2003; Hagell and Cenci, 2005; Piccini et al.,
2005). In animal models, Soderstrom et al. (2008) revealed novel
dyskinetic behaviors, i.e., orolingual and contralateral forelimb
dyskinesia that emerged and increased with escalating immune
activation using allografts with peripheral spleen cell injections,
whereas the inflammatory response itself using proinflammatory
cytokines or orthotopic skin allograft is not sufficient to evoke
dyskinetic behaviors (Lane et al., 2008).
Ultrastructural analysis using electron microscopy shows
a positive correlation between GID severity and proportion
of aberrant synaptic features in the parkinsonian striatum.
Instead of synapsing onto the neck of the MSNs spines (and
glutamatergic endings to the head) grafted DA neurons formed
new synapses onto the dendrites directly instead of spines.
This change was found enhanced with immune activation
and to be significantly correlated with GID (Soderstrom et al.,
2008). Inflammation may thus interfere with the appropriate
synapse formation between graft and host-neurons. Indeed,
elevated expression of synaptogenesis genes is linked to
inflammation and inflammatory factors can increase the
synaptic strength and AMPA receptor trafficking (Beattie
et al., 2002; Yukhananov and Kissin, 2008). Aberrant synaptic
profiles that might excessively excite the activity within the
grafted striatum can give rise to aberrant focal output similar
to the sustained LTP seen in LID (Picconi et al., 2003). A
consideration for future clinical trials should therefore be a
careful evaluation of the value of long-term immunosuppression
following neural transplantation or perhaps attempting
to prevent the dendritic spine loss using calcium channel
antagonists.
CONCLUSION
L-DOPA causes long term changes in the anatomical and
neurochemical make up of the striatum and in particular
corticostriatal connections, all of which have been correlated
to LID. Although complex, there has been some work trying
to identify how these changes may influence the development
of GID. Critically, avoiding patients with established significant
LID may be the current pathway to successful transplantation;
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a model being adopted by the ongoing EU funded clinical trial
TransEuro. One of the major limitations in understanding both
LID and in particular GID has been the animal models and
the parity between them and the patients. Currently our models
of PD are oversimplified and nigrostriatal denervation alone is
unlikely to be providing us with the true physiological insight
into a patients’ brain. Nevertheless, exploring both LID and GID
is giving us a greater understanding of exactly how the brain is
capable of changing in certain environments and the functional
consequences that result. Whether we can undo these changes, or
only work to avoid their occurrence in the first place, remains to
be seen.
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